Navigation Links
MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
Date:6/18/2010

sclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

---------------------------------

[1] The NYHA clinical classifications of heart failure rank patients as Class I-II-III-IV, according to the degree of symptoms or functional limits, from asymptomatic to bed ridden. MADIT-CRT patients are asymptomatic or mildly symptomatic, NYHA Class I (ischemic) and Class II (ischemic and non-ischemic).

[2] High-risk is defined as QRS width >130 milliseconds with Left Ventricular Ejection Fraction < 30 percent and Left Bundle Branch Block (LBBB). LBBB is a condition in which the activation of the left ventricle is delayed. As a result, portions of the left ventricle contract later than the rest of the left ventricle and right ventricle, reducing the heart's pumping ability.

    Contact:

    Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    David Knutson
    +1-651-582-6574 (office)
    +1-651-260-8288 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Phase III Trial Finds Pharmaxis Bronchitol Effective
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a ... and genetic deficiencies that result in metabolic disorders, announced ... Form S-1 with the U.S. Securities and Exchange Commission ... shares of its common stock. The number of shares ... offering have not yet been determined. Citigroup ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
(Date:8/27/2014)... August 27, 2014 “We are honored ... vendors,” said Ven Thangaraj, CEO of Radiant Sage. “We ... are taking the imaging corelab market to a different ... and research organizations to efficiently and effectively manage the ... data to be analyzed and read by trained physicians. ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... N.J., July 21 BioNeutral Group, Inc. ("BioNeutral") (OTC ... Science Company announced today that at ATS Labs using ... Antimicrobial passed the difficult Quantitative Disk Carrier test ... difficile (C.diff) present in this test ...
... , , PALO ALTO, Calif., July 21, ... third quarter of its fiscal year 2009 after 1:00 p.m. Pacific Time ... of its investor conference call to review those quarterly results is scheduled ... , That live webcast can be accessed from Varian, ...
... , , KENILWORTH, N.J., July 21 ... for the 2009 second quarter. , , ... given us the strength to again power through tough challenges - delivering ... Fred Hassan, chairman and CEO. , , ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3Schering-Plough Reports Financial Results for 2009 Second Quarter 2Schering-Plough Reports Financial Results for 2009 Second Quarter 3Schering-Plough Reports Financial Results for 2009 Second Quarter 4Schering-Plough Reports Financial Results for 2009 Second Quarter 5Schering-Plough Reports Financial Results for 2009 Second Quarter 6Schering-Plough Reports Financial Results for 2009 Second Quarter 7Schering-Plough Reports Financial Results for 2009 Second Quarter 8Schering-Plough Reports Financial Results for 2009 Second Quarter 9Schering-Plough Reports Financial Results for 2009 Second Quarter 10Schering-Plough Reports Financial Results for 2009 Second Quarter 11Schering-Plough Reports Financial Results for 2009 Second Quarter 12Schering-Plough Reports Financial Results for 2009 Second Quarter 13Schering-Plough Reports Financial Results for 2009 Second Quarter 14Schering-Plough Reports Financial Results for 2009 Second Quarter 15Schering-Plough Reports Financial Results for 2009 Second Quarter 16Schering-Plough Reports Financial Results for 2009 Second Quarter 17Schering-Plough Reports Financial Results for 2009 Second Quarter 18Schering-Plough Reports Financial Results for 2009 Second Quarter 19Schering-Plough Reports Financial Results for 2009 Second Quarter 20Schering-Plough Reports Financial Results for 2009 Second Quarter 21Schering-Plough Reports Financial Results for 2009 Second Quarter 22Schering-Plough Reports Financial Results for 2009 Second Quarter 23Schering-Plough Reports Financial Results for 2009 Second Quarter 24Schering-Plough Reports Financial Results for 2009 Second Quarter 25Schering-Plough Reports Financial Results for 2009 Second Quarter 26Schering-Plough Reports Financial Results for 2009 Second Quarter 27
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... number of studies have shown that excessive ... of Parkinson,s disease. Previous studies from Chunyan ... in China have shown that baicalin prevented ... divalent metal transporter 1 expression, and increased ... of rotenone-induced Parkinson,s disease rats. However, the ...
(Date:8/27/2014)... of seven hours ago the Happy Camp Complex of ... California, the July complex had consumed 35,530 as of ... fires on the Happy Camp Ranger District of the ... area on August 11, 2014. All but three of ... is a list of contained fires and their size ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... your body is telling you that your pace feels a little ... A new study, published online March 18 in the ... human running varies with speed and that each individual has an ... distance with the least effort. The result debunks the ...
... millions of people with diseases that starve eye tissue ... procedure being developed by researchers at Oak Ridge National ... of Tennessee. The technique uses a new class ... tissue being deprived of oxygen because of restricted blood ...
... of the benefits of cooling strategies to protect the ... to a wealth of cutting edge research, prime examples ... of Journal of Neurotrauma , a peer-reviewed journal ... The issue will be available free online at ...
Cached Biology News:Optimum running speed is stride toward understanding human body form 2ORNL, Southern Cal set sights on preventing blindness 2Therapeutic hypothermia is promising strategy to minimize tissue damage 2
... pulsed field separations of DNA larger than 2, ... megabase pairs. This agarose has the highest gel strength of any ... ... ...
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Mouse monoclonal antibody to Lats2....
... Membrane Protein 2, Synaptobrevin 2). ... homology with any other known ... expected that the antibody will ... multata and bovine due to ...
Biology Products: